Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602467903> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2602467903 abstract "6514^ Background: Ruxolitinib is a potent and selective JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) based on results of the phase 3 COMFORT studies. Ruxolitinib demonstrated rapid and durable reductions in splenomegaly and improved MF-related symptoms and quality of life of patients (pts) with MF. Since one measure of efficacy is molecular response, this analysis correlates changes in mutant allele burden (%V617F) with spleen size reduction in COMFORT-II. Methods: COMFORT-II is a randomized, open-label, phase 3 study comparing ruxolitinib 15 or 20 mg twice daily (BID) with BAT. The primary endpoint was a ≥ 35% reduction in spleen volume from baseline (BL) at week 48. Change in %V617F was measured by allele specific qPCR. Pts were stratified by reduction in %V617F (< 10%, 10-20%, > 20%) and results were correlated with achievement of the primary endpoint. Results: More pts in the ruxolitinib arm had ≥ 10% V617F reductions compared with BAT (41% vs 5%; P = .01; Table). The majority of reductions > 20% were gradual and progressive over the course of the study; 2 pts had rapid reductions from 48% to 1% and 45% to 9% over 48 weeks. In the ruxolitinib arm, significantly more pts with a > 20% V617F reduction achieved the primary endpoint compared with pts with a < 10% reduction (79% vs 30%; P = .004); in each group, gender did not affect spleen response. For pts with < 10% reductions (15 mg BID, n = 16; 20 mg BID, n = 24), the average total daily dose (TDD) was ruxolitinib 29.6 mg; pts with > 20% reductions (15 mg BID, n = 3; 20 mg BID, n = 11) had a TDD of 35.3 mg. Conclusions: Pts who received ruxolitinib had larger reductions in JAK2V617F allele burden compared with BAT. %V617F reductions were gradual over the course of the 48-week study; longer follow-up is needed to determine the extent of allele burden reduction. [Table: see text]" @default.
- W2602467903 created "2017-04-07" @default.
- W2602467903 creator A5000563949 @default.
- W2602467903 creator A5001595006 @default.
- W2602467903 creator A5004841984 @default.
- W2602467903 creator A5008609620 @default.
- W2602467903 creator A5009381933 @default.
- W2602467903 creator A5018111458 @default.
- W2602467903 creator A5041036069 @default.
- W2602467903 creator A5046147242 @default.
- W2602467903 creator A5046772202 @default.
- W2602467903 creator A5046827092 @default.
- W2602467903 creator A5049331182 @default.
- W2602467903 creator A5053069175 @default.
- W2602467903 creator A5069072959 @default.
- W2602467903 creator A5089433535 @default.
- W2602467903 creator A5091547978 @default.
- W2602467903 date "2012-05-20" @default.
- W2602467903 modified "2023-10-07" @default.
- W2602467903 title "Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT)." @default.
- W2602467903 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.6514" @default.
- W2602467903 hasPublicationYear "2012" @default.
- W2602467903 type Work @default.
- W2602467903 sameAs 2602467903 @default.
- W2602467903 citedByCount "6" @default.
- W2602467903 countsByYear W26024679032013 @default.
- W2602467903 countsByYear W26024679032014 @default.
- W2602467903 countsByYear W26024679032015 @default.
- W2602467903 crossrefType "journal-article" @default.
- W2602467903 hasAuthorship W2602467903A5000563949 @default.
- W2602467903 hasAuthorship W2602467903A5001595006 @default.
- W2602467903 hasAuthorship W2602467903A5004841984 @default.
- W2602467903 hasAuthorship W2602467903A5008609620 @default.
- W2602467903 hasAuthorship W2602467903A5009381933 @default.
- W2602467903 hasAuthorship W2602467903A5018111458 @default.
- W2602467903 hasAuthorship W2602467903A5041036069 @default.
- W2602467903 hasAuthorship W2602467903A5046147242 @default.
- W2602467903 hasAuthorship W2602467903A5046772202 @default.
- W2602467903 hasAuthorship W2602467903A5046827092 @default.
- W2602467903 hasAuthorship W2602467903A5049331182 @default.
- W2602467903 hasAuthorship W2602467903A5053069175 @default.
- W2602467903 hasAuthorship W2602467903A5069072959 @default.
- W2602467903 hasAuthorship W2602467903A5089433535 @default.
- W2602467903 hasAuthorship W2602467903A5091547978 @default.
- W2602467903 hasConcept C104317684 @default.
- W2602467903 hasConcept C126322002 @default.
- W2602467903 hasConcept C143998085 @default.
- W2602467903 hasConcept C180754005 @default.
- W2602467903 hasConcept C2776112149 @default.
- W2602467903 hasConcept C2780007613 @default.
- W2602467903 hasConcept C2780076729 @default.
- W2602467903 hasConcept C54355233 @default.
- W2602467903 hasConcept C71924100 @default.
- W2602467903 hasConcept C86803240 @default.
- W2602467903 hasConceptScore W2602467903C104317684 @default.
- W2602467903 hasConceptScore W2602467903C126322002 @default.
- W2602467903 hasConceptScore W2602467903C143998085 @default.
- W2602467903 hasConceptScore W2602467903C180754005 @default.
- W2602467903 hasConceptScore W2602467903C2776112149 @default.
- W2602467903 hasConceptScore W2602467903C2780007613 @default.
- W2602467903 hasConceptScore W2602467903C2780076729 @default.
- W2602467903 hasConceptScore W2602467903C54355233 @default.
- W2602467903 hasConceptScore W2602467903C71924100 @default.
- W2602467903 hasConceptScore W2602467903C86803240 @default.
- W2602467903 hasLocation W26024679031 @default.
- W2602467903 hasOpenAccess W2602467903 @default.
- W2602467903 hasPrimaryLocation W26024679031 @default.
- W2602467903 hasRelatedWork W1976651396 @default.
- W2602467903 hasRelatedWork W1981098678 @default.
- W2602467903 hasRelatedWork W2051887590 @default.
- W2602467903 hasRelatedWork W2092462163 @default.
- W2602467903 hasRelatedWork W2105235256 @default.
- W2602467903 hasRelatedWork W2111872404 @default.
- W2602467903 hasRelatedWork W2115351357 @default.
- W2602467903 hasRelatedWork W2121743767 @default.
- W2602467903 hasRelatedWork W2184879058 @default.
- W2602467903 hasRelatedWork W2202630195 @default.
- W2602467903 hasRelatedWork W2318650733 @default.
- W2602467903 hasRelatedWork W2320073799 @default.
- W2602467903 hasRelatedWork W2553304123 @default.
- W2602467903 hasRelatedWork W2564300741 @default.
- W2602467903 hasRelatedWork W2587303462 @default.
- W2602467903 hasRelatedWork W2600689467 @default.
- W2602467903 hasRelatedWork W2772311550 @default.
- W2602467903 hasRelatedWork W2903989375 @default.
- W2602467903 hasRelatedWork W2939342812 @default.
- W2602467903 hasRelatedWork W3016444371 @default.
- W2602467903 isParatext "false" @default.
- W2602467903 isRetracted "false" @default.
- W2602467903 magId "2602467903" @default.
- W2602467903 workType "article" @default.